| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genome-Wide Association Study | 23 | 2024 | 1638 | 3.130 |
Why?
|
| Polymorphism, Single Nucleotide | 31 | 2023 | 2581 | 3.110 |
Why?
|
| Lung Neoplasms | 28 | 2024 | 1591 | 3.050 |
Why?
|
| Genetic Predisposition to Disease | 27 | 2023 | 3074 | 2.140 |
Why?
|
| Selection, Genetic | 6 | 2024 | 155 | 2.080 |
Why?
|
| Melanoma | 7 | 2024 | 824 | 1.820 |
Why?
|
| Genome, Human | 15 | 2020 | 1264 | 1.810 |
Why?
|
| Skin Neoplasms | 7 | 2024 | 796 | 1.790 |
Why?
|
| Mutation, Missense | 13 | 2024 | 845 | 1.630 |
Why?
|
| Codon, Nonsense | 3 | 2022 | 131 | 1.510 |
Why?
|
| Prostatic Neoplasms | 11 | 2017 | 1512 | 1.490 |
Why?
|
| Gene Expression Profiling | 10 | 2019 | 1679 | 1.270 |
Why?
|
| Neoplasms | 7 | 2020 | 2758 | 1.160 |
Why?
|
| Neoplasm Proteins | 4 | 2018 | 667 | 1.110 |
Why?
|
| Genes, Neoplasm | 2 | 2019 | 80 | 1.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2023 | 1872 | 0.940 |
Why?
|
| Gene Frequency | 6 | 2022 | 713 | 0.940 |
Why?
|
| Quantitative Trait Loci | 4 | 2022 | 282 | 0.800 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 7 | 2023 | 332 | 0.780 |
Why?
|
| X Chromosome | 1 | 2023 | 337 | 0.780 |
Why?
|
| Computational Biology | 6 | 2015 | 796 | 0.770 |
Why?
|
| Scleroderma, Systemic | 2 | 2019 | 117 | 0.750 |
Why?
|
| Frameshift Mutation | 2 | 2019 | 175 | 0.740 |
Why?
|
| Biological Evolution | 5 | 2015 | 221 | 0.680 |
Why?
|
| Biomarkers, Tumor | 8 | 2024 | 1439 | 0.670 |
Why?
|
| Genetic Variation | 6 | 2020 | 1475 | 0.660 |
Why?
|
| Germ-Line Mutation | 2 | 2020 | 313 | 0.650 |
Why?
|
| Mutation | 8 | 2024 | 5764 | 0.650 |
Why?
|
| Humans | 74 | 2024 | 123072 | 0.610 |
Why?
|
| Models, Statistical | 3 | 2019 | 473 | 0.550 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2020 | 1012 | 0.550 |
Why?
|
| RNA Splicing | 3 | 2014 | 222 | 0.520 |
Why?
|
| Genomics | 2 | 2014 | 1475 | 0.500 |
Why?
|
| Blood | 1 | 2015 | 105 | 0.500 |
Why?
|
| Gene Expression | 2 | 2018 | 1565 | 0.480 |
Why?
|
| Exons | 4 | 2014 | 794 | 0.480 |
Why?
|
| Alleles | 5 | 2020 | 1603 | 0.480 |
Why?
|
| Crossing Over, Genetic | 4 | 2001 | 50 | 0.470 |
Why?
|
| Genes, p53 | 2 | 2005 | 213 | 0.460 |
Why?
|
| Carcinogenesis | 1 | 2017 | 328 | 0.460 |
Why?
|
| Logistic Models | 7 | 2022 | 1798 | 0.430 |
Why?
|
| Environmental Exposure | 1 | 2015 | 217 | 0.430 |
Why?
|
| Introns | 1 | 2014 | 301 | 0.420 |
Why?
|
| Male | 49 | 2024 | 60081 | 0.420 |
Why?
|
| Algorithms | 5 | 2016 | 1592 | 0.400 |
Why?
|
| Meiosis | 7 | 2001 | 115 | 0.400 |
Why?
|
| Chromosomes, Human, Pair 15 | 4 | 2018 | 159 | 0.390 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2024 | 651 | 0.390 |
Why?
|
| Lung | 4 | 2023 | 1463 | 0.370 |
Why?
|
| Case-Control Studies | 15 | 2024 | 3239 | 0.370 |
Why?
|
| Cryptorchidism | 4 | 2012 | 37 | 0.370 |
Why?
|
| Recombination, Genetic | 4 | 2001 | 446 | 0.370 |
Why?
|
| Genotype | 14 | 2016 | 2533 | 0.370 |
Why?
|
| CpG Islands | 4 | 2023 | 320 | 0.370 |
Why?
|
| Receptors, Nicotinic | 5 | 2012 | 154 | 0.360 |
Why?
|
| Oncogenes | 2 | 2022 | 168 | 0.360 |
Why?
|
| Evolution, Molecular | 1 | 2014 | 672 | 0.350 |
Why?
|
| Breast Neoplasms | 2 | 2019 | 2480 | 0.350 |
Why?
|
| Chromosomes, Human, Pair 5 | 3 | 2019 | 117 | 0.350 |
Why?
|
| Genes, Essential | 1 | 2009 | 40 | 0.340 |
Why?
|
| Genetics, Population | 3 | 2017 | 185 | 0.330 |
Why?
|
| Databases, Nucleic Acid | 2 | 2008 | 69 | 0.320 |
Why?
|
| Disease | 1 | 2010 | 129 | 0.320 |
Why?
|
| DNA Methylation | 3 | 2024 | 983 | 0.320 |
Why?
|
| Membrane Proteins | 3 | 2019 | 1522 | 0.320 |
Why?
|
| Neoplasm Staging | 5 | 2024 | 1213 | 0.300 |
Why?
|
| Chromosomes | 3 | 2000 | 199 | 0.290 |
Why?
|
| Carcinoma, Small Cell | 1 | 2007 | 50 | 0.290 |
Why?
|
| Organ Specificity | 2 | 2019 | 423 | 0.280 |
Why?
|
| Smoking | 8 | 2024 | 1031 | 0.270 |
Why?
|
| Adenocarcinoma | 6 | 2020 | 993 | 0.270 |
Why?
|
| Telomerase | 3 | 2019 | 161 | 0.260 |
Why?
|
| Homozygote | 4 | 2001 | 532 | 0.260 |
Why?
|
| Female | 31 | 2024 | 65528 | 0.250 |
Why?
|
| Survival Analysis | 2 | 2019 | 1473 | 0.240 |
Why?
|
| Point Mutation | 1 | 2006 | 348 | 0.230 |
Why?
|
| Reproducibility of Results | 4 | 2022 | 2826 | 0.230 |
Why?
|
| Receptors, G-Protein-Coupled | 3 | 2010 | 279 | 0.230 |
Why?
|
| Regulatory Sequences, Ribonucleic Acid | 1 | 2003 | 16 | 0.220 |
Why?
|
| Heterozygote | 4 | 2020 | 672 | 0.210 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2004 | 298 | 0.210 |
Why?
|
| Odds Ratio | 3 | 2022 | 1244 | 0.210 |
Why?
|
| Homeodomain Proteins | 2 | 2002 | 544 | 0.200 |
Why?
|
| Prognosis | 10 | 2024 | 4513 | 0.200 |
Why?
|
| Receptors, Androgen | 3 | 2016 | 408 | 0.200 |
Why?
|
| Nucleotides | 1 | 2022 | 92 | 0.200 |
Why?
|
| DNA-Binding Proteins | 3 | 2022 | 2055 | 0.190 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2020 | 93 | 0.190 |
Why?
|
| Chromosome Mapping | 5 | 2012 | 1081 | 0.190 |
Why?
|
| Conserved Sequence | 1 | 2022 | 293 | 0.180 |
Why?
|
| Receptors, Cell Surface | 2 | 2002 | 469 | 0.180 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2020 | 17 | 0.180 |
Why?
|
| Risk Factors | 16 | 2020 | 10016 | 0.180 |
Why?
|
| Proteins | 3 | 2018 | 1037 | 0.180 |
Why?
|
| Silent Mutation | 1 | 2020 | 3 | 0.180 |
Why?
|
| Chromosome Inversion | 2 | 1991 | 76 | 0.180 |
Why?
|
| Middle Aged | 21 | 2024 | 25992 | 0.170 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2003 | 548 | 0.170 |
Why?
|
| Open Reading Frames | 2 | 2014 | 210 | 0.170 |
Why?
|
| Genetic Association Studies | 2 | 2022 | 759 | 0.170 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2019 | 31 | 0.170 |
Why?
|
| Ultraviolet Rays | 1 | 2020 | 203 | 0.170 |
Why?
|
| Promoter Regions, Genetic | 1 | 2023 | 1339 | 0.160 |
Why?
|
| Aged | 16 | 2024 | 19094 | 0.160 |
Why?
|
| Principal Component Analysis | 2 | 2017 | 142 | 0.160 |
Why?
|
| Mammals | 1 | 2000 | 262 | 0.160 |
Why?
|
| Mucins | 1 | 2019 | 74 | 0.160 |
Why?
|
| Mutation Rate | 1 | 2018 | 66 | 0.160 |
Why?
|
| Risk | 1 | 2020 | 745 | 0.150 |
Why?
|
| Multivariate Analysis | 1 | 2022 | 1412 | 0.150 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 142 | 0.150 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2017 | 17 | 0.140 |
Why?
|
| Leukocytes | 1 | 2018 | 207 | 0.140 |
Why?
|
| Autoimmunity | 1 | 2018 | 172 | 0.140 |
Why?
|
| Linkage Disequilibrium | 3 | 2012 | 309 | 0.140 |
Why?
|
| Linear Models | 1 | 2019 | 669 | 0.140 |
Why?
|
| Testis | 3 | 2012 | 405 | 0.140 |
Why?
|
| Karyotyping | 6 | 2000 | 330 | 0.130 |
Why?
|
| Mice | 12 | 2012 | 17538 | 0.130 |
Why?
|
| Finasteride | 1 | 2016 | 16 | 0.130 |
Why?
|
| Computer Simulation | 2 | 2014 | 630 | 0.130 |
Why?
|
| Cell Cycle Proteins | 2 | 2012 | 643 | 0.130 |
Why?
|
| Phenotype | 7 | 2018 | 4221 | 0.130 |
Why?
|
| MicroRNAs | 1 | 2022 | 827 | 0.130 |
Why?
|
| Models, Genetic | 4 | 2008 | 760 | 0.120 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2012 | 33 | 0.120 |
Why?
|
| Prostatectomy | 1 | 2016 | 332 | 0.120 |
Why?
|
| Inflammation | 2 | 2012 | 1403 | 0.120 |
Why?
|
| Colonic Neoplasms | 1 | 2017 | 245 | 0.120 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2018 | 591 | 0.110 |
Why?
|
| Alternative Splicing | 2 | 2007 | 349 | 0.110 |
Why?
|
| Gene Expression Regulation | 2 | 2019 | 2524 | 0.100 |
Why?
|
| Life Style | 1 | 2015 | 402 | 0.100 |
Why?
|
| Interleukin-2 Receptor beta Subunit | 1 | 2012 | 5 | 0.100 |
Why?
|
| Robotic Surgical Procedures | 1 | 2016 | 194 | 0.100 |
Why?
|
| Precision Medicine | 1 | 2015 | 305 | 0.100 |
Why?
|
| DNA Transposable Elements | 1 | 1993 | 177 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 280 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2012 | 140 | 0.100 |
Why?
|
| Cocarcinogenesis | 1 | 2011 | 23 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 171 | 0.090 |
Why?
|
| Software | 1 | 2016 | 674 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2023 | 164 | 0.090 |
Why?
|
| Cluster Analysis | 1 | 2012 | 400 | 0.090 |
Why?
|
| Ligaments | 1 | 2010 | 18 | 0.090 |
Why?
|
| Cardiovascular Diseases | 2 | 2020 | 1862 | 0.090 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2011 | 76 | 0.090 |
Why?
|
| Laparoscopy | 1 | 2016 | 501 | 0.090 |
Why?
|
| Animals | 14 | 2012 | 33791 | 0.090 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2010 | 75 | 0.080 |
Why?
|
| Genotyping Techniques | 2 | 2020 | 101 | 0.080 |
Why?
|
| beta Catenin | 1 | 2010 | 205 | 0.080 |
Why?
|
| Mice, Transgenic | 3 | 2012 | 2395 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 3 | 2012 | 1112 | 0.080 |
Why?
|
| Receptors, Notch | 1 | 2010 | 202 | 0.080 |
Why?
|
| Survival Rate | 2 | 2012 | 1997 | 0.080 |
Why?
|
| Genes, Overlapping | 1 | 2008 | 7 | 0.080 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 653 | 0.070 |
Why?
|
| 5' Untranslated Regions | 1 | 2008 | 59 | 0.070 |
Why?
|
| Disease Progression | 2 | 2013 | 2023 | 0.070 |
Why?
|
| 3' Untranslated Regions | 1 | 2008 | 165 | 0.070 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 6371 | 0.070 |
Why?
|
| Europe | 2 | 2019 | 350 | 0.070 |
Why?
|
| Sex Factors | 1 | 2011 | 1261 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 2109 | 0.070 |
Why?
|
| Signal Transduction | 3 | 2012 | 4490 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 561 | 0.070 |
Why?
|
| Spermatocytes | 1 | 1986 | 22 | 0.070 |
Why?
|
| DNA, Recombinant | 1 | 2006 | 100 | 0.070 |
Why?
|
| Adult | 8 | 2024 | 29010 | 0.070 |
Why?
|
| Bone Neoplasms | 1 | 2010 | 430 | 0.070 |
Why?
|
| PAX6 Transcription Factor | 2 | 2002 | 37 | 0.060 |
Why?
|
| Paired Box Transcription Factors | 2 | 2002 | 75 | 0.060 |
Why?
|
| Insulin | 1 | 2010 | 1200 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2002 | 1290 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 2014 | 0.060 |
Why?
|
| Polymorphism, Genetic | 2 | 2007 | 807 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2007 | 467 | 0.060 |
Why?
|
| Protein Isoforms | 2 | 2002 | 408 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2005 | 228 | 0.060 |
Why?
|
| Genetic Markers | 3 | 1993 | 604 | 0.060 |
Why?
|
| Eye Proteins | 2 | 2002 | 217 | 0.060 |
Why?
|
| 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 1 | 2004 | 21 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2016 | 3016 | 0.060 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2004 | 70 | 0.060 |
Why?
|
| Chromosome Aberrations | 2 | 2023 | 614 | 0.060 |
Why?
|
| Smokers | 1 | 2024 | 39 | 0.060 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2003 | 37 | 0.060 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2003 | 54 | 0.060 |
Why?
|
| Haplotypes | 3 | 2011 | 517 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2007 | 1389 | 0.050 |
Why?
|
| Molecular Sequence Data | 3 | 2002 | 3868 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 1702 | 0.050 |
Why?
|
| Relaxin | 1 | 2002 | 15 | 0.050 |
Why?
|
| Blotting, Northern | 1 | 2002 | 258 | 0.050 |
Why?
|
| Brain Chemistry | 1 | 2002 | 122 | 0.050 |
Why?
|
| Retrospective Studies | 4 | 2024 | 16039 | 0.050 |
Why?
|
| Folic Acid | 1 | 2004 | 292 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2023 | 4703 | 0.050 |
Why?
|
| DNA Primers | 1 | 2002 | 660 | 0.050 |
Why?
|
| Amino Acid Substitution | 1 | 2002 | 389 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 1986 | 555 | 0.050 |
Why?
|
| Gene Deletion | 3 | 2012 | 792 | 0.050 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 892 | 0.050 |
Why?
|
| Eye | 1 | 2002 | 227 | 0.050 |
Why?
|
| Repressor Proteins | 2 | 2002 | 810 | 0.050 |
Why?
|
| Tumor Burden | 2 | 2012 | 230 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 3293 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2003 | 528 | 0.040 |
Why?
|
| Jews | 1 | 2020 | 32 | 0.040 |
Why?
|
| Postmenopause | 1 | 2020 | 125 | 0.040 |
Why?
|
| Research Design | 1 | 2024 | 678 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 477 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 530 | 0.040 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2004 | 544 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2001 | 500 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2023 | 664 | 0.040 |
Why?
|
| Gene Ontology | 1 | 2018 | 48 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2003 | 1017 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2022 | 576 | 0.040 |
Why?
|
| Young Adult | 3 | 2018 | 8836 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2020 | 470 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 1265 | 0.040 |
Why?
|
| Coronary Disease | 1 | 2020 | 637 | 0.030 |
Why?
|
| Pedigree | 1 | 2020 | 1576 | 0.030 |
Why?
|
| HapMap Project | 1 | 2016 | 12 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2002 | 2809 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 351 | 0.030 |
Why?
|
| Transgenes | 2 | 2010 | 334 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 409 | 0.030 |
Why?
|
| Pathology, Molecular | 1 | 2015 | 58 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 268 | 0.030 |
Why?
|
| Phylogeny | 1 | 2017 | 693 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2016 | 278 | 0.030 |
Why?
|
| Biomarkers | 1 | 2023 | 2944 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2015 | 300 | 0.030 |
Why?
|
| Chromosome Banding | 2 | 1991 | 139 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 669 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2002 | 4352 | 0.030 |
Why?
|
| Probability | 1 | 2013 | 321 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2013 | 312 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 2013 | 462 | 0.030 |
Why?
|
| Texas | 2 | 2012 | 3563 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2016 | 458 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2016 | 1590 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 2016 | 294 | 0.020 |
Why?
|
| Regression Analysis | 1 | 1993 | 767 | 0.020 |
Why?
|
| Sperm Count | 1 | 2012 | 75 | 0.020 |
Why?
|
| Airway Remodeling | 1 | 2011 | 21 | 0.020 |
Why?
|
| Patient Safety | 1 | 2016 | 394 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 2012 | 136 | 0.020 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2011 | 33 | 0.020 |
Why?
|
| Activin Receptors, Type I | 1 | 2011 | 33 | 0.020 |
Why?
|
| Tissue Distribution | 2 | 2002 | 382 | 0.020 |
Why?
|
| Age of Onset | 1 | 2012 | 581 | 0.020 |
Why?
|
| Organ Size | 1 | 2012 | 412 | 0.020 |
Why?
|
| Adolescent | 3 | 2018 | 19096 | 0.020 |
Why?
|
| Muscle Development | 1 | 2010 | 71 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2016 | 626 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 861 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 2 | 2002 | 752 | 0.020 |
Why?
|
| Actins | 1 | 2012 | 341 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 2803 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 1990 | 183 | 0.020 |
Why?
|
| Genes | 1 | 2010 | 444 | 0.020 |
Why?
|
| Apoptosis | 1 | 2016 | 1782 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2011 | 790 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2010 | 262 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 1584 | 0.020 |
Why?
|
| Infertility, Male | 1 | 2012 | 262 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 2307 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 664 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2010 | 741 | 0.020 |
Why?
|
| Heart Failure | 1 | 2020 | 2127 | 0.020 |
Why?
|
| Cysteine Endopeptidases | 1 | 2008 | 114 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2002 | 2696 | 0.020 |
Why?
|
| Testosterone | 1 | 2012 | 462 | 0.020 |
Why?
|
| 11-Hydroxycorticosteroids | 1 | 1986 | 1 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2008 | 452 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2010 | 996 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 1986 | 311 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2012 | 936 | 0.020 |
Why?
|
| Models, Biological | 1 | 2010 | 1443 | 0.020 |
Why?
|
| Aneuploidy | 1 | 1986 | 153 | 0.020 |
Why?
|
| Registries | 1 | 2012 | 1395 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2018 | 8109 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 5048 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2010 | 1909 | 0.010 |
Why?
|
| Infant | 1 | 2018 | 12355 | 0.010 |
Why?
|
| Base Sequence | 1 | 2007 | 3092 | 0.010 |
Why?
|
| Urinary Bladder | 1 | 2004 | 242 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2002 | 129 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2018 | 13881 | 0.010 |
Why?
|
| Luciferases | 1 | 2002 | 137 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2002 | 313 | 0.010 |
Why?
|
| Glycine | 1 | 2002 | 167 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2008 | 994 | 0.010 |
Why?
|
| Plasmids | 1 | 2002 | 511 | 0.010 |
Why?
|
| Contig Mapping | 1 | 2001 | 55 | 0.010 |
Why?
|
| Pigmentation | 1 | 2001 | 35 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2002 | 482 | 0.010 |
Why?
|
| Transfection | 1 | 2002 | 1068 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2016 | 12123 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2002 | 1100 | 0.010 |
Why?
|
| Spermatogenesis | 1 | 2001 | 166 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 657 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2002 | 674 | 0.010 |
Why?
|
| Infertility | 1 | 2001 | 90 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2001 | 757 | 0.010 |
Why?
|
| Peptides | 1 | 2002 | 794 | 0.010 |
Why?
|
| Protein Binding | 1 | 2002 | 1742 | 0.010 |
Why?
|
| Child | 1 | 2018 | 24226 | 0.010 |
Why?
|
| Diet | 1 | 2004 | 1127 | 0.010 |
Why?
|
| DNA | 1 | 2002 | 1589 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2001 | 4286 | 0.010 |
Why?
|
| Siberia | 1 | 1988 | 4 | 0.000 |
Why?
|
| Animals, Wild | 1 | 1988 | 24 | 0.000 |
Why?
|